Multimodal Imaging Demonstrates Antifibrotic Effects of Targeting αvβ6/αvβ1 Integrins in Biliary Fibrosis
A single imaging protocol combining molecular MRI and PET can be used to effectively monitor integrin inhibitor treatment by measuring target expression/engagement and treatment outcomes. Multimodality molecular imaging may be valuable in accelerating drug development in molecular therapies for liver fibrosis.
Authors
- Scott Turner (ORCID: https://orcid.org/0000-0002-6618-6405)
- Peter Caravan (ORCID: https://orcid.org/0000-0002-3179-6537)
- Avery T. Boice (ORCID: https://orcid.org/0009-0004-2722-2524)
- Nicholas J. Rotile (ORCID: https://orcid.org/0000-0001-6568-9927)
- Iris Y. Zhou (ORCID: https://orcid.org/0000-0002-4351-7398)
- Yingying Ning (ORCID: https://orcid.org/0000-0002-2942-2202)
- İlknur Ay (ORCID: https://orcid.org/0000-0001-9558-742X)
- Johanna Schaub
Institutions
- Athinoula A. Martinos Center for Biomedical Imaging (US)
Publication Details
- Journal
- Investigative Radiology
- Published
- 2025-05-01
- DOI
- https://doi.org/10.1097/rli.0000000000001202
- Citations
- 1
- Primary Topic
- Liver Diseases and Immunity
- Type
- article
- Field-Weighted Citation Impact
- 1.32